GWM
FOLD

Geneos Wealth Management’s Amicus Therapeutics FOLD Stock Holding History

Geneos Wealth Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-850
Closed -$4.87K – 2741
2025
Q2 		$4.87K Buy
850
+153
+22% +$987 ﹤0.01% 2586
2025
Q1 		$12.9K Buy
697
+600
+619% +$5.55K ﹤0.01% 2488
2024
Q4 		$914 Buy
97
+5
+5% +$52 ﹤0.01% 2789
2024
Q3 		$983 Buy
+92
New +$1K ﹤0.01% 2450
2024
Q2 		– Sell
-65
Closed -$766 – 2106
2024
Q1 		$766 Buy
+65
New +$831 ﹤0.01% 2077
2017
Q1 		– Sell
-4,258
Closed -$21K – 2088
2016
Q4 		$21K Buy
+4,258
New +$29.5K ﹤0.01% 1162

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geneos Wealth Management's FOLD Position: Q3 2025 in Review

Geneos Wealth Management sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 850 shares — an estimated $4.87K sold.

Geneos Wealth Management first reported a position in FOLD in Q4 2016 and held it in 6 quarters. The position peaked at $21K in Q4 2016. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Geneos Wealth Management reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 850 Amicus Therapeutics shares in Q3 2025, an estimated $4.87K.
  • Geneos Wealth Management first reported a position in Amicus Therapeutics in Q4 2016 and held it in 6 quarters.
  • Geneos Wealth Management's Amicus Therapeutics position peaked at $21K in Q4 2016.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.